Isabel Schemainda
Astellas Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Isabel Schemainda.
Clinical Cancer Research | 2005
Manickam Muruganandham; Alan A. Alfieri; Cornelia Matei; Yuchun Chen; George Sukenick; Isabel Schemainda; Max Hasmann; Leonard Saltz; Jason A. Koutcher
Purpose: Attempts to selectively initiate tumor cell death through inducible apoptotic pathways are increasingly being exploited as a potential anticancer strategy. Inhibition of NAD+ synthesis by a novel agent FK866 has been recently reported to induce apoptosis in human leukemia, hepatocarcinoma cells in vitro, and various types of tumor xenografts in vivo. In the present study, we used 1H-decoupled phosphorus (31P) magnetic resonance spectroscopy (MRS) to examine the metabolic changes associated with FK866 induced tumor cell death in a mouse mammary carcinoma. Experimental Design: Induction of apoptosis in FK866-treated tumors was confirmed by histology and cytofluorometric analysis. FK866-induced changes in mammary carcinoma tumor metabolism in vivo were investigated using 1H-decoupled 31P MRS. To discern further the changes in metabolic profiles of tumors observed in vivo, high-resolution in vitro 1H-decoupled 31P MRS studies were carried out with perchloric acid extracts of mammary carcinoma tumors excised after similar treatments. In addition, the effects of FK866 on mammary carcinoma tumor growth and radiation sensitivity were studied. Results: Treatment with FK866 induced a tumor growth delay and enhanced radiation sensitivity in mammary carcinoma tumors that was associated with significant increases in the 31P MR signal in the phosphomonoester region and a decrease in NAD+ levels, pH, and bioenergetic status. The 31P MRS of perchloric acid extracts of treated tumors identified the large unresolved signal in the phosphomonoester region as the resultant of resonances originating from intermediates of tumor glycolysis and guanylate synthesis in addition to alterations in pyridine nucleotide pools and phospholipid metabolism. Conclusion: The present results suggest that FK866 interferes with multiple biochemical pathways that contribute to the increased cell death (apoptosis) and subsequent radiation sensitivity observed in the mammary carcinoma that could be serially monitored by 31P MRS.
Cancer Research | 2003
Max Hasmann; Isabel Schemainda
Cancer Research | 2002
Katja Wosikowski; Karin Mattern; Isabel Schemainda; Max Hasmann; Benno Rattel; Roland Löser
Archive | 2000
Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt; Katja Wosikowski; Isabel Schemainda
Archive | 2000
Elfi Biedermann; Rolf Eisenburger; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Isabel Schemainda; Michael Schulz; Klaus Seibel; Klaus Vogt; Katja Wosikowski
Archive | 2000
Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt; Katia Wosikowski; Isabel Schemainda
Archive | 1999
Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Isabel Schemainda; Klaus Seibel; Klaus Vogt; Katja Wosikowski
Archive | 1997
Rolf Eisenburger; Friedemann Reiter; Isabel Schemainda; Klaus Seibel
Archive | 2000
Elfi Biedermann; Max Hasmann; Roland Löser; Benno Rattel; Friedemann Reiter; Barbara Schein; Klaus Seibel; Klaus Vogt; Katja Wosikowski; Isabel Schemainda
Archive | 1998
Elfi Biedermann; Max Hasmann; Roland Dr Loeser; Benno Rattel; Friedemann Reiter; Barbara Schein; Isabel Schemainda; Klaus Seibel; Klaus Vogt; Katja Wosikowski